Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 [SPECIAL ARTICLE]

Conclusion
PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease manifestations most likely to affect prognosis adversely for therapeutics tested in both nonmetastatic and metastatic CRPC populations. Consultation with regulatory authorities is recommended if a trial is intended to seek support for drug approval.

Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Scher, Morris, Stadler, Higano, Basch, Fizazi, Antonarakis, Beer, Carducci, Chi, Corn, de Bono, Dreicer, George, Heath, Hussain, Kelly, Liu, Logothetis, Nanus, Stein, Rathkopf, Slovin, Ryan, Sartor, Small, Smith, Sternberg, Taplin, Wilding, Nelson, Schwar Tags: Systemic Therapy, Combined Modality Therapy SPECIAL ARTICLE Source Type: research